Gastroenterology

Controversies in Management of HBV:
Lessons from Case Studies

This CME activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME activities may not contain the most up-to-date information available.

Click here to view our current activities in Gastroenterology.

Controversies in Management of HBV: Lessons from Case Studies

Order CD-ROM

In this interactive CD-ROM, clinicians will apply knowledge of epidemiology, natural history, virology, and treatment to case studies representing the complex presentations and histories seen in today's clinical practice. In the course of a clinician's day, not all decision points have obvious answers. Neither will the decision points in these case studies. Our faculty panel will use these cases and decision points to discuss the controversies of HBV management. Issues will include: risk factors for progression of disease and development of hepatocellular carcinoma (HCC); immunosuppression; inactive carriers; posttreatment reactivation of infection; end-stage liver disease and liver transplant; durability of response; viral variants; liver biopsy; pregnancy and prevention of maternal transmission; and endpoints of therapy.

CHAIR
Robert G. Gish, MD Medical Director Liver Transplant Program Chief, Division of Hepatology and Complex GI California Pacific Medical Center San Francisco, California
FACULTY
W. Ray Kim, MD Associate Professor of Medicine Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota	Robert P. Perrillo, MD Director, Academic Affairs Gastroenterology and Hepatology Ochsner Clinic Foundation New Orleans, Louisiana
Mindie H. Nguyen, MD, MAS Assistant Professor of Medicine Stanford University Medical Center Palo Alto, California

top

TARGET AUDIENCE

This interactive CD-ROM is designed for gastroenterologists, hepatologists, and other clinicians who care for patients with hepatitis B infection or those at increased risk for acquiring the infection.

ACTIVITY GOAL

The goal of Controversies in Management of HBV: Lessons from Case Studies is to examine current and emerging strategies for diagnosing and treating patients infected with HBV.

LEARNING OBJECTIVES

Identify patients at risk for HBV infection and risk factors for disease progression and HCC, including the significance of a positive family history.
Incorporate viral factors, such as e-antigen status, and patient factors, such as immunocompetence, into individualized treatment plans.
Utilize endpoint measurements to guide ongoing treatment decisions, including decisions to stop therapy.
Discuss the risk of posttreatment disease flares and implement appropriate prevention and monitoring strategies.
Manage HBV infection during pregnancy to reduce the risk of maternal transmission.
Recognize and manage the long-term sequelae of untreated HBV infection, including end-stage liver disease.

top

CME INFORMATION

Statement of Accreditation

Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge designates this educational activity for a maximum of 3.0 Category 1 credits toward the AMA Physician's Recognition Award.

This independent CME activity is planned and implemented in accordance with the ACCME Essential Areas and Policies.

CME INFORMATION: PHYSICIAN ASSISTANTS

This program has been reviewed and is approved for a maximum of 3.0 hours of AAPA Category 1 (Preapproved) CME credit by the Physician Assistant Review Panel. Approval is valid for one year from the issue date of October 12, 2005. Participants may submit the self-assessment (posttest) at any time during that period.

Successful completion of the self-assessment (posttest) is required to earn Category 1 (Preapproved) CME credit. Successful completion is defined as a cumulative score of at least 70% correct.

This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

CE INFORMATION: NURSES

This activity has been approved by the American Association of Critical-Care Nurses (AACN) for 3.5 contact hours. Provider #00012705.

Contract for Mutual Responsibility in CME/CE
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.

top

DISCLOSURE INFORMATION

The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.

For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).

Robert G. Gish, MD, has disclosed affiliations with Bayer Pharmaceutical Corporation (grant/research support, consultant, speakers bureau, and honoraria), Bristol-Myers Squibb Company (grant/research support, consultant, speakers bureau, and honoraria), Bristol-Myers Squibb Company Entecavir Global Advisory Panel (grant/research support, consultant, speakers bureau, and honoraria), Eximias Pharmaceutical Corporation (grant/research support, consultant, speakers bureau, and honoraria), Gilead Sciences Inc (grant/research support, consultant, speakers bureau, and honoraria), GlaxoSmithKline (grant/research support, consultant, speakers bureau, and honoraria), Human Genome Sciences (consultant), InterMune Inc (grant/research support, consultant, speakers bureau, and honoraria), Ortho Biotech Products, LP (grant/research support, consultant, speakers bureau, and honoraria), Roche Pharmaceuticals (grant/research support, consultant, speakers bureau, and honoraria), Schering-Plough Corporation (grant/research support, consultant, speakers bureau, and honoraria), SciClone Pharmaceuticals (grant/research support, consultant, speakers bureau, and honoraria), United Therapeutics (grant/research support), Valeant Pharmaceuticals International (grant/research support, consultant, speakers bureau, and honoraria), XTL Biopharmaceuticals Ltd (grant/research support). Dr. Gish has indicated that he will reference unlabeled/unapproved uses of adefovir, entecavir, and peginterferon.

W. Ray Kim, MD, has disclosed an affiliation with Bristol-Myers Squibb Company (consultant). Dr. Kim has indicated that he will be referencing the unlabeled/unapproved use of tenofovir.

Mindie H. Nguyen, MD, MAS, has disclosed affiliations with Bristol-Myers Squibb Company (advisory board), Gilead Sciences Inc (advisory board), O-Gen (consultant), Roche Pharmaceuticals (grant/research support and advisory board), and Salix Pharmaceuticals, Inc (advisory board). Dr. Nguyen has indicated that she will not be referencing any unlabeled/unapproved uses of drugs or devices.

Robert P. Perrillo, MD, has disclosed affiliations with Gilead Sciences Inc (consultant, advisory board, and honoraria), GlaxoSmithKline (consultant, advisory board, and speakers bureau), Roche Pharmaceuticals (grant/research support, consultant, advisory board, and honoraria), Schering-Plough Corporation (grant/research support and honoraria), and Vertex Pharmaceuticals Incorporated (grant/research support). Dr. Perrillo has indicated that he will be referencing the unlabeled/unapproved use of peginterferon.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge's staff members have no significant relationships to disclose.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

This independent CME/CE activity is supported by an educational grant from
Bristol-Myers Squibb Company.

top

1718